Medical Microbiology and Immunology

, Volume 204, Issue 3, pp 247–254 | Cite as

The history of vaccination against cytomegalovirus

  • Stanley PlotkinEmail author
Part of the following topical collections:
  1. Cytomegalovirus


Cytomegalovirus vaccine development started in the 1970s with attenuated strains. In the 1980s, one of the strains was shown to be safe and effective in renal transplant patients. Then, attention switched to glycoprotein gB, which was shown to give moderate but transient protection against acquisition of the virus by women. The identification of the pp65 tegument protein as the principal target of cellular immune responses resulted in new approaches, particularly DNA, plasmids to protect hematogenous stem cell recipients. The subsequent discovery of the pentameric protein complex that generates most neutralizing antibodies led to efforts to incorporate that complex into vaccines. At this point, there are many candidate CMV vaccines, including live recombinants, replication-defective virus, DNA plasmids, soluble pentameric proteins, peptides, virus-like particles and vectored envelope proteins.


Vaccination Vaccine trials Towne strain 



Figure 3 is reprinted with permission from Elsevier (The Lancet, 2011, 377(9773):1256-1263).


  1. 1.
    Ho M (2008) The history of cytomegalovirus and its diseases. Med Microbiol Immunol 197(2):65–73CrossRefPubMedGoogle Scholar
  2. 2.
    Reddehase MJ, Koszinowski UH (1984) Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312:369–371CrossRefPubMedGoogle Scholar
  3. 3.
    Stagno S, Pass RF, Cloud G et al (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256(14):1904–1908CrossRefPubMedGoogle Scholar
  4. 4.
    Dollard SC, Grosse SD, Ross DS (2007) New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17(5):355–363CrossRefPubMedGoogle Scholar
  5. 5.
    Limaye AP, Bakthavatsalam R, Kim HW et al (2006) Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12):1645–1652CrossRefPubMedGoogle Scholar
  6. 6.
    Ljungman P, Hakki M, Boeckh M (2010) Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24(2):319–337CrossRefPubMedGoogle Scholar
  7. 7.
    Osawa R, Singh N (2009) Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care 13(3):R68CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Koch S, Larbi A, Ozcelik D et al (2007) Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 1114:23–35CrossRefPubMedGoogle Scholar
  9. 9.
    Elek SD, Stern H (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1(7845):1–5CrossRefPubMedGoogle Scholar
  10. 10.
    Plotkin SA, Furukawa T, Zygraich N, Huygelen C (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12(3):521–527PubMedCentralPubMedGoogle Scholar
  11. 11.
    Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR (1979) Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 160(1):32–37CrossRefPubMedGoogle Scholar
  12. 12.
    Spaete RR (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23(Suppl. 3):90–96PubMedGoogle Scholar
  13. 13.
    Stratton KR, Durch JS, Lawrence RS (2001) Vaccines for the 21st century. A tool for decisionmaking. Committee to study priorities for vaccine development. Division of health promotion and disease prevention, Institute of Medicine, The National Academies, WashingtonGoogle Scholar
  14. 14.
    Plotkin SA, Huygelen C (1976) Cytomegalovirus vaccine prepared in WI-38. Dev Biol Stand 37:301–305PubMedGoogle Scholar
  15. 15.
    Plotkin SA, Farquhar J, Hornberger E (1976) Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 134(5):470–475CrossRefPubMedGoogle Scholar
  16. 16.
    Just M, Buergin-Wolff A, Emoedi G, Hernandez R (1975) Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection 3(2):111–114CrossRefPubMedGoogle Scholar
  17. 17.
    Fleisher GR, Starr SE, Friedman HM, Plotkin SA (1982) Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child 136(4):294–296PubMedGoogle Scholar
  18. 18.
    Quinnan GVJ, Delery M, Rook AH et al (1984) Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 101(4):478–483CrossRefPubMedGoogle Scholar
  19. 19.
    Adler SP, Hempfling S, Starr S et al (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Ped Infect Dis J 17:200–206CrossRefGoogle Scholar
  20. 20.
    Starr SE, Glazer JP, Friedman HM, Farquhar JD, Plotkin SA (1981) Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 143(4):585–589CrossRefPubMedGoogle Scholar
  21. 21.
    Carney WP, Hirsch MS, Iacoviello VR, Starr SE, Fleisher G, Plotkin SA (1983) T-lymphocyte subsets and proliferative responses following immunization with cytomegalovirus vaccine. J Infect Dis 147(5):958CrossRefPubMedGoogle Scholar
  22. 22.
    Jacobson MA, Sinclair E, Bredt B et al (2006) Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 35(3):332–337CrossRefPubMedGoogle Scholar
  23. 23.
    Friedman AD, Furukawa T, Plotkin SA (1982) Detection of antibody to cytomegalovirus early antigen in vaccinated, normal volunteers and renal transplant candidates. J Infect Dis 146(2):255–259CrossRefPubMedGoogle Scholar
  24. 24.
    Friedman AD, Michelson S, Plotkin SA (1982) Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine. Infect Immun 38(3):1068–1072PubMedCentralPubMedGoogle Scholar
  25. 25.
    Cha TA, Edward T, Kemble W, Duke GM, Mocarski E, Spaete R (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70(1):78–83PubMedCentralPubMedGoogle Scholar
  26. 26.
    Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW (2001) A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 11(3):191–200CrossRefPubMedGoogle Scholar
  27. 27.
    Plotkin SA, Huang ES (1985) Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 152(2):395–397CrossRefPubMedGoogle Scholar
  28. 28.
    Plotkin SA, Weibel RE, Alpert G et al (1985) Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. J Infect Dis 151(4):737–739CrossRefPubMedGoogle Scholar
  29. 29.
    Plotkin SA, Higgins R, Kurtz JB et al (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58:1176–1178CrossRefPubMedGoogle Scholar
  30. 30.
    Adler SP, Starr SE, Plotkin SA et al (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171(1):26–32CrossRefPubMedGoogle Scholar
  31. 31.
    Heineman TC, Schleiss M, Bernstein DI et al (2006) A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193(10):1350–1360CrossRefPubMedGoogle Scholar
  32. 32.
    Gonczol E, Hudecz F, Ianacone J, Dietzschold B, Starr S, Plotkin SA (1986) Immune responses to isolated human cytomegalovirus envelope proteins. J Virol 58:661–664PubMedCentralPubMedGoogle Scholar
  33. 33.
    Gonczol E, Ianacone J, Ho W (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune responses in human volunteers. Vaccine 8:130–136CrossRefPubMedGoogle Scholar
  34. 34.
    Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64(3):1079–1085PubMedCentralPubMedGoogle Scholar
  35. 35.
    Frey SE, Harrison C, Pass RF et al (1999) Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 180(5):1700–1703CrossRefPubMedGoogle Scholar
  36. 36.
    Pass RF, Duliege AM, Boppana S et al (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180(4):970–975CrossRefPubMedGoogle Scholar
  37. 37.
    Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP (2002) Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 21(2):133–138CrossRefPubMedGoogle Scholar
  38. 38.
    Pass RF, Zhang C, Evans A et al (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360(12):1191–1199CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Sabbaj S, Pass RF, Goepfert PA, Pichon S (2011) Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 203(11):1534–1541CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Pass R (2010) Slide presentation by Robert Pass at ICAAC meeting in 2010 Update on CMV Vaccines Google Scholar
  41. 41.
    Bernstein DI, Munoz FM, Callahan ST et al (2014) Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine. Pediatric Academic Societies Meeting, AbstractGoogle Scholar
  42. 42.
    Griffiths PD, Stanton A, McCarrell E et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377(9773):1256–1263CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Walter EA, Greenberg PD, Gilbert MJ et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333(16):1038–1044CrossRefPubMedGoogle Scholar
  44. 44.
    Gyulai Z, Endresz V, Burian K et al (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181(5):1537–1546CrossRefPubMedGoogle Scholar
  45. 45.
    Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101(7):2686–2692CrossRefPubMedGoogle Scholar
  46. 46.
    Malouli D, Hansen SG, Nakayasu ES et al (2014) Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest 124(5):1928–1944CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Diamond DJ, York J, Sun JY, Wright CL, Forman SJ (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90(5):1751–1767PubMedGoogle Scholar
  48. 48.
    Wloch MK, Smith LR, Boutsaboualoy S et al (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197(12):1634–1642CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Kharfan-Dabaja MA, Boeckh M, Wilck MB et al (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12(4):290–299CrossRefPubMedGoogle Scholar
  50. 50.
    Smith LR, Wloch MK, Chaplin JA et al (2013) Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. Vaccines 1:398–414CrossRefGoogle Scholar
  51. 51.
    Shedlock DJ, Talbott KT, Wu SJ et al (2012) Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother 8(11):1668–1681CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Loomis RJ, Lilja AE, Monroe J et al (2013) Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31(6):919–926CrossRefPubMedGoogle Scholar
  53. 53.
    Lilja AE, Mason PW (2012) The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 30(49):6980–6990CrossRefPubMedGoogle Scholar
  54. 54.
    Bernstein DI, Reap EA, Katen K et al (2009) Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28(2):484–493CrossRefPubMedGoogle Scholar
  55. 55.
    Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102(50):18153–18158CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Wang D, Li F, Freed DC et al (2011) Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29(48):9075–9080CrossRefPubMedGoogle Scholar
  57. 57.
    Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, Gerna G (2011) Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 52(2):113–118CrossRefPubMedGoogle Scholar
  58. 58.
    Lilleri D, Kabanova A, Revello MG et al (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8(3):e59863CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Hahn G, Revello MG, Patrone M et al (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78(18):10023–10033CrossRefPubMedCentralPubMedGoogle Scholar
  60. 60.
    Wen Y, Monroe J, Linton C et al (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32(30):3796–3804CrossRefPubMedGoogle Scholar
  61. 61.
    Fu TM, Wang D, Freed DC et al (2012) Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30(52):7469–7474CrossRefPubMedGoogle Scholar
  62. 62.
    Fu TM, An Z, Wang D (2014) Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32(22):2525–2533CrossRefPubMedGoogle Scholar
  63. 63.
    Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109(36):14604–14609CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.
    Becke S, Aue S, Thomas D et al (2010) Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. Vaccine 28(38):6191–6198CrossRefPubMedGoogle Scholar
  65. 65.
    Cayatte C, Schneider-Ohrum K, Wang Z et al (2013) Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J Virol 87(20):11107–11120CrossRefPubMedCentralPubMedGoogle Scholar
  66. 66.
    La RC, Longmate J, Lacey SF et al (2012) Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 205(8):1294–1304CrossRefGoogle Scholar
  67. 67.
    Kirchmeier M, Fluckiger AC, Soare C et al (2014) Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol 21(2):174–180CrossRefPubMedCentralPubMedGoogle Scholar
  68. 68.
    Macagno A, Bernasconi NL, Vanzetta F et al (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84(2):1005–1013CrossRefPubMedCentralPubMedGoogle Scholar
  69. 69.
    Barkai G, Ari-Even RD, Barzilai A et al (2014) Universal neonatal cytomegalovirus screening using saliva—report of clinical experience. J Clin Virol 60(4):361–366CrossRefPubMedGoogle Scholar
  70. 70.
    Lanzieri TM, Bialek SR, Ortega-Sanchez IR, Gambhir M (2014) Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine 32(30):3780–3786CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Emeritus Professor of PediatricsUniversity of PennsylvaniaDoylestownUSA

Personalised recommendations